Pegloticase

Excerpt

Pegloticase, an FDA-approved pegylated, recombinant uricase, helps manage chronic gout refractory to standard therapy among adult patients. Since its approval in 2010, this drug has demonstrated efficacy by catalyzing uric acid into the water-soluble purine metabolite allantoin, facilitating its easy excretion. This activity discusses pegloticase's indications, mechanisms of action, and contraindications, emphasizing its indispensable role in treating and managing chronic gout that remains unresponsive to conventional therapeutic approaches. Attendees will become more knowledgeable about pegloticase therapy, including its adverse event profile, enabling interprofessional team members involved in caring for patients with chronic gout and related conditions to make informed decisions within a clinical setting.